.

Thursday, August 22, 2019

Case study Example | Topics and Well Written Essays - 500 words - 103

Case Study Example While Genzyme’s focus on orphan drugs can be questioned, on the face of it, this decision was a pragmatic one as is also substantiated by the tangible success of the company. Owing to its production of drugs for rare diseases it was easier for the company to target its markets, although essentially smaller than those for the widely-needed drugs, more systematically and sustainably. Moreover its focus on orphan drugs also made it possible for the company to accrue full benefits of tax breaks and market exclusivity contained in the Orphan Drug Act introduced by FDA in 1983 thus multiplying the chances of Genzyme’s domination of the already-limited orphan drugs’ market. As far as the strategic intent of Genzyme is concerned the company it’s a long term one as is being depicted by the company’s diversification of the drugs it produces. In addition to its focus on orphan drugs it is also producing common drugs so as to secure its share of the bigger markets too which can ensure accruing continued profit by the company and hence further cement its position in the pharmaceutical industry. Although Genzyme is actively pursuing diversification of its market through production of common drugs too the company should retain its focus on orphan drugs as the incidence of rare diseases such as certain kidney disorders and forms of cancer, whose cure is offered by the orphan drugs, is continually on the rise. Moreover, as the company’s exemplary success testifies to the latent practicality of its decision of focusing on orphan drugs it should take steps towards further specialized areas of medicine and medical technology so as to sustain its distinct position in the industry rather than plunging into the arena of common medicine characterized by fierce competition. Moreover if the company works towards integration of modern medical technology with its products it can add to the breadth of its market further. In

No comments:

Post a Comment